Chelsea Combs

TL;DR: Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, it is found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.

TL;DR: Targeted concomitant endogenous expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas reveals the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.

TL;DR: The findings suggest that productive tumor immunity may be undermined from the start, and efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer.

TL;DR: In this article, the authors defined the genetic requirements for pancreatic ductal adenocarcinoma (PDA) and targeted concomitant endogenous expression of Trp53 R172H and Kras G12D to reveal the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.

TL;DR: In this article, the authors show that concomitant expression of Kras(G12D) and haploinsufficiency of the Smad4/Dpc4 tumor suppressor gene engenders a distinct class of pancreatic tumors, mucinous cystic neoplasms (MCNs), which culminate in invasive ductal adenocarcinomas.